Javier Pascual

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients

E. Alba, C. Ramírez-Tortosa, P. Sánchez‐Rovira, 2014, Clinical and Translational Oncology.

Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients

L. Vicioso, Alicia Garrido-Aranda, A. Godoy-Ortiz, 2024, NPJ breast cancer.

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

L. Comerma, S. Servitja, O. Arpí, 2024, Journal of experimental & clinical cancer research : CR.